EMA seeks executive director

Andreas Pott will be acting executive director until position is filled

The European Medicines Agency (EMA) is seeking a new executive director. Its current head, Thomas Lönngren, is leaving the post on 31 December, following the end of his second five-year mandate.

While EMA searches for a permanent replacement, its current head of administration, Andreas Pott, will serve as acting executive director.

University of Hamburg graduate, Pott has been the agency’s administration chief since 2000, having previously worked for the European Parliament and the EU’s translation service.

Swede Lönngren is a former deputy director-general of the Swedish Medical Products Agency (MPA).

You may also like

Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development

EVerZom and GENFIT partner for research collaboration for liver failure candidate EViv

The agreement will support EVerZom’s dynamic development strategy and follows the recent announcement of a €10m financing round aimed at accelerating its clinical and partnering roadmap
You need to be a subscriber to read this article.
Click here to find out more.
Pharma 5.0

Three ways AI is changing the chemicals and materials industry

With AI technologies continuing to make their mark on almost every sector, the materials and chemicals industry is no exception, reports Cameron Ross, Senior Vice President of Generative AI at Elsevier
Manufacturing

Watson-Marlow to showcase advanced fluid path solutions at COMPAMED 2025

The fluid transfer solution specialist will highlight a variety of peristaltic pumps and associated fluid path technologies at this years COMPAMED 2025, taking place from 17-20 Nov in Düsseldorf, Germany
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
You need to be a subscriber to read this article.
Click here to find out more.
Personal Protection

Gas safety in smaller pharmaceutical facilities

Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees
Sustainability

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti
Subscribe now